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Abstract. The apolipoprotein E (APOE) gene has been consistently shown to modulate the risk of Alzheimer’s disease (AD).
Here, using an AD and normal aging dataset primarily consisting of three AD multi-center studies (n = 1,781), we compared
the effect of APOE and amyloid- (A) on baseline hippocampal volumes in AD patients, mild cognitive impairment (MCI)
subjects, and healthy controls. A large sample of healthy adolescents (n = 1,387) was also used to compared hippocampal
volumes between APOE groups. Subjects had undergone a magnetic resonance imaging (MRI) scan and APOE genotyping.
Hippocampal volumes were processed using FreeSurfer. In the AD and normal aging dataset, hippocampal comparisons
were performed in each APOE group and in 4 carriers with positron emission tomography A who were dichotomized
(A+/A–) using previous cut-offs. We found a linear reduction in hippocampal volumes with 4 carriers possessing the
smallest volumes, 3 carriers possessing intermediate volumes, and 2 carriers possessing the largest volumes. Moreover, AD
and MCI 4 carriers possessed the smallest hippocampal volumes and control 2 carriers possessed the largest hippocampal
volumes. Subjects with both APOE 4 and A+ had the lowest hippocampal volumes when compared to A- 4 carriers,
suggesting a synergistic relationship between APOE 4 and A. However, we found no hippocampal volume differences
between APOE groups in healthy 14-year-old adolescents. Our findings suggest that the strongest neuroanatomic effect of
APOE 4 on the hippocampus is observed in AD and groups most at risk of developing the disease, whereas hippocampi of
old and young healthy individuals remain unaffected.
Keywords: Alzheimer’s disease, amyloid, APOE 4, hippocampus, magnetic resonance imaging, mild cognitive impairment
INTRODUCTION
The apolipoprotein E (APOE) gene is a well-
established genetic risk factor for the development of
late-onset Alzheimer’s disease (AD) and since its dis-
covery, a large body of research has been conducted
to explain its role in AD pathophysiology [1–3]. The
APOE 4 allele, a genetic risk factor known to sub-
stantially increase the risk of AD in a dose-dependent
fashion, is associated with higher amyloid- (A)
deposition [4, 5]. By contrast, the APOE 2 allele has
been suggested to confer a protective effect against
AD [6].
Hippocampal volumetry has been shown to be
a sensitive, albeit non-specific marker of neurode-
generation in AD. Previously, it has been used to
demonstrate accelerated rates of hippocampal atro-
phy in 4 carriers with amnestic mild cognitive
impairment (MCI) [7, 8]. Although the exact tem-
porospatial relationship between A and tau in the
pathological cascade of AD is unclear, it has been sug-
gested that both proteinopathies may have a synergis-
tic effect on neuronal toxicity [9]. Emerging data also
suggests that these pathological processes that influ-
ence cognitive decline in AD are moderated by APOE
4 through both A-dependent and A-independent
mechanisms [10]. However, evidence for the direct
mechanistic actions of APOE 4 is mixed.
Despite the numerous studies, our limited under-
standing of APOE 4 risk in asymptomatic
individuals and individuals with varying stages of AD
pathophysiology warrants further study. Evidence
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has suggested that equivocal findings in neuroimag-
ing studies of APOE 4 may be attributed to the lack
of specificity between changes that are due to normal
aging and those that manifest as a result of patho-
logical neurodegeneration [11]. Furthermore, some
APOE neuroimaging findings originate from stud-
ies with limitations in sample size and hence study
power [12]. This is further exacerbated by the varying
distribution of APOE 4 carrier status across differ-
ent samples. However, recent neuroimaging APOE
studies with well-characterized samples (between
400–700 subjects) are beginning to address this
methodological issue [13, 14]. Also, recent neu-
roimaging evidence from young APOE 4 carriers
has also shown that structural and functional alter-
ations in the brain may precede A pathology
[15, 16]. This had led researchers to postulate that that
APOE 4 may exert neurodevelopmental changes
that provide a foothold for the pathological cascade
of AD later in life.
In order to capture the heterogeneity of varying
AD risk, we combined several well-characterized
cohort studies to evaluate neuroanatomic the effect
of APOE genotype on hippocampal volumes. The
first dataset in our study, known as the AD and nor-
mal aging dataset (n = 1,781) consisted of imaging
data from three large multi-center AD consortiums,
(i) The Alzheimer’s Disease Neuroimaging Initia-
tive (ADNI), (ii) the AddNeuroMed study (ANM),
and (iii) the Australian Imaging, Biomarkers and
Lifestyles (AIBL) study, as well as a sample of
non-demented individuals from the Swedish National
Study on Aging and Care in Kungsholmen (SNAC-K)
and a dementia study from King’s College London,
UK (BRC-AD). The sample of non-demented indi-
viduals from the SNAC-K study were considered
separate from healthy controls as the recruitment
criteria for these subjects was epidemiological in
nature and we could not exclude the possibility of
memory impairment in some subjects. In our second
dataset, we used a large sample of healthy 14-year-
old adolescents (n = 1,387) in order to determine
the neurodevelopmental effect of APOE 4 geno-
type on hippocampal volume. This is particularly
important because adolescence is a time of substan-
tial dynamic neurobiological and behavioral changes.
These changes are often beneficial and can optimize
the brain for adult maturation, but can also confer
neural vulnerabilities for certain types of psychiatric
or neurological illness.
The aim of this study was to firstly evaluate
the neuroanatomic effect of APOE genotype on the
hippocampus in the AD and normal aging dataset.
Previous studies have demonstrated a linear effect
of APOE genotype on disease risk, with 2 carri-
ers possessing a low risk of developing AD, and 4
carriers possessing the greatest risk [17]. We aimed
to test if this linear stepwise effect of APOE geno-
type also imparted a similar neuroanatomic effect on
the hippocampus across the different stages of AD
pathophysiology. We then tested the neuroanatomic
effect of APOE genotype on hippocampal volumes
of healthy 14-year-old adolescents to determine the
role of APOE in adolescent brain development.
On the other hand, converging evidence suggests
that APOE 4 modifies A accumulation and may
have downstream effects on tau neurodegeneration
[18]. To further elucidate the mechanisms of this pro-
posed synergistic relationship, we aimed to examine
whether high levels of A deposition would lead to
greater hippocampal loss compared to low levels of
A deposition in APOE 4 carriers.
MATERIALS AND METHOD
Datasets
Cohort specific inclusion criteria and details of the
study design can be found in previous publications
[19–23]. Table 1 provides details of the number of
subjects from each cohort included in the AD and
normal aging dataset.
AD and Normal Aging Dataset (n = 1,781)
Alzheimer’s Disease Neuroimaging Initiative
(n = 779)
A detailed description of the study design can
be found on the ADNI webpage (http://www.adni-
info.org). Data was obtained for subjects from
the ADNI online database (http://adni.loni.usc.edu).
Subjects were between 55 and 90 years of age. ADNI
was approved by the institutional review board and
ethics committees of participating institutions, and
written informed consent was obtained from all par-
ticipants or their next of kin.
i. AD (n= 177): General inclusion/exclusion cri-
teria: 1) MMSE scores between 20 and 26; 2)
CDR of 0.5 or 1.0; 3) met NINCDS/ADRDA
criteria for probable AD.
ii. MCI (n= 383): General inclusion/exclusion
criteria: 1) subjects had MMSE scores between
24 and 30 (inclusive); 2) memory complaint
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Table 1
Number of subjects obtained from each cohort study in the AD and normal aging dataset (n = 1,781)
Cohort Study Clinical Diagnosis Number of subjects (%)
Alzheimer’s Disease Neuroimaging Initiative (n = 779) Alzheimer’s disease 177 (22.7%)
Mild Cognitive Impairment 383 (49.2%)
Healthy Controls 219 (28.1%)
AddNeuroMed study (n = 303) Alzheimer’s disease 109 (36.0%)
Mild Cognitive Impairment 97 (32.0%)
Healthy Controls 97 (32.0%)
Australian, Imaging, Biomarkers and Lifestyles (AIBL) study (n = 228) Alzheimer’s disease 46 (20.2%)
Mild Cognitive Impairment 42 (18.4%)
Healthy Controls 140 (61.4%)
Biomedical Research Centre for Dementia, King’s College London
(BRC-AD) study (n = 89)
Alzheimer’s disease 33 (37.1%)
Healthy Controls 56 (62.9%)
Swedish National study on aging and care in Kungscholmen (SN-ACK)
(n = 382)
Healthy Controls 382 (100%)
had objective memory loss measured by edu-
cation adjusted scores on Wechsler Memory
Scale Logical Memory II; 3) CDR of 0.5; 4)
absence of significant levels of impairment in
other cognitive domains, essentially preserved
activities of daily living, and an absence of
dementia.
iii. Cognitively normal (CN) (n= 219): General
inclusion/exclusion criteria: 1) MMSE scores
between 24 and 30 (inclusive); 2) CDR of zero;
3) they were non- depressed, non MCI, and
non-demented.
AddNeuroMed (ANM) study (n= 303)
Information regarding the study design and enrol-
ment criteria has been previously described elsewhere
[21, 24]. All AD and MCI subjects were recruited
from the local memory clinics of one of the six partic-
ipating sites while the control subjects were recruited
from non-related members of the patient’s families,
caregiver’s relatives, and social centers for the elderly
or GP surgeries. ANM was approved by the South
London and Maudsley NHS Foundation Trust ethics
committee and other ethical review boards of each
participating country. Ethics committee approval was
obtained at each of the participating centers in accor-
dance with the Alzheimer’s Associations published
recommendations.
i. AD (n= 109): Inclusion criteria: 1)
ADRDA/NINCDS and DSM-IV criteria
for probable AD. 2) Mini-Mental State Exam-
ination (MMSE) score ranged from 12 to 28;
3) age 65 years or above. Exclusion criteria:
1) Significant neurological or psychiatric
illness other than AD; 2) Significant unstable
systematic illness or organ failure.
ii. MCI (n= 97) and CN (n= 97): Inclusion cri-
teria: 1) MMSE score range between 24 and
30; 2) Geriatric Depression Scale score less
than or equal to 5; 3) age 65 years or above;
4) medication stable; 5) good general health.
Exclusion criteria: 1) met the DSM-IV crite-
ria for dementia; 2) significant neurological or
psychiatric illness other than AD; 3) significant
unstable systematic illness or organ failure.
iii. The distinction between MCI and CN indi-
viduals was based on two criteria: 1)
subject scores 0 on Clinical Dementia Rat-
ing Scale (CDR) = CN; 2) Subject scores 0.5
on CDR = MCI. For the MCI subjects, it
was preferable that the subject and informant
reported occurrence of memory problems. All
AD subjects had a CDR score of 0.5 or
above.
The Australian, Imaging, Biomarkers, and
Lifestyles (AIBL) study (n= 228)
The AIBL study is a prospective longitudinal
study of aging, integrating data from neuroimaging,
biomarkers, lifestyle, clinical, and neuropsycholog-
ical analysis. Detailed information about the study
design has been described in previous publications
[20, 25]. CN individuals were recruited by adver-
tisement in the community while MCI and AD
patients were recruited from tertiary memory dis-
orders clinics or private geriatricians, psychiatrists,
and neurologists that subspecialize in dementia.
All participants were at least 60 years of age,
in good general health with no history of stroke
or other neurological disease. The institutional
ethics committees of Austin Health, St Vincent’s
Health, Hollywood Private Hospital and Edith
Cowan University approved the AIBL study, and
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all volunteers gave written informed consent before
participating.
i. AD (n= 46): Inclusion criteria: 1) all met
NINCDS-ADRDA criteria for probable AD;
2) had a CDR of 1 or more.
ii. MCI (n= 42): Inclusion criteria: 1) met criteria
of subjective and objective cognitive difficul-
ties in the absence of significant functional
loss; 2) had a CDR of less than 1. 52 MCI
participants fulfilled criteria for “amnestic”
MCI, and 5 were non-amnestic cases (4 were
non-amnestic multi-domain and 1 was non-
amnestic single domain).
iii. CN (n= 140): Inclusion criteria: participants
were separated in those who reported subjec-
tive memory complaints (n = 95) and those who
did not (n = 82), according to their response to
the question: “Do you have any difficulty with
your memory?”
Biomedical Research Centre for Mental Health
and Dementia Cohort, King’s College London
(BRC-AD) (n= 89)
BRC-AD is a neuroimaging study which was
designed to establish imaging markers for the earlier
detection and diagnosis of AD. Data was collected at
the Institute of Psychiatry, Psychology, and Neuro-
science, King’s College London, UK. A total of 89
subjects (AD: 33, CN:56) were obtained with APOE
data for this study. Diagnostic inclusion and exclu-
sion criteria for this study were exactly the same as
for the ANM study.
Swedish National study on Aging and Care
in Kungsholmen (SNAC-K) study (n= 382)
Participants were recruited from a larger
population-based epidemiological study, the SNAC-
K. In this study, participants were randomly selected
to take part from the island of Kungsholmen in cen-
tral Stockholm to examine aging in late adulthood
[26]. During the first data collection, a subsample of
non-institutionalized and non-disabled participants
were randomly selected to undergo MRI. Participants
with dementia diagnoses, schizophrenia diagnosis,
bipolar disorder diagnosis, self-reported stroke,
stroke observed on MRI, self-reported Parkinson’s
disease, or epilepsy, were excluded. The study design
has been described in detail elsewhere [22]. We used
a sample of 459 individuals from SNAC-K, who
underwent MRI imaging and APOE genotyping.
77 subjects with suboptimal MRI images and
neurological and/or psychiatric conditions were
excluded. The SNAC-K study was population-based,
therefore subjects in this sample were considered
a heterogeneous sample of elderly participants and
treated separate from our sample CN individuals.
The SNAC-K study complies with the declaration
of Helsinki, and has been approved by the ethical
committee at Karolinska Institutet. All subjects gave
informed consent, and in the case of severe cogni-




This is the first European multi-center study
combining genetics with behavioral and neu-
ropsychological measures, functional and structural
neuroimaging, and genome-wide association anal-
yses in 2,000 healthy 14-year-old adolescents. A
description of the study design are provided in
Schumann et al. [23]. We selected 1,387 healthy ado-
lescents with available MRI data and ApoE status
information.
Genome-wide genotyping was performed using
Illumina Quad 610 and 660 arrays (San Diego,
CA, USA). Quality control of the genome-wide
data was performed and samples with the follow-
ing criteria were excluded: genotype call rate < 95%,
and those with discordance between clinical and
genotypic gender. Single nucleotide polymorphisms
(SNP) quality control filters were used as described
in the ENIGMA consortium imputation pro-
tocol (http://enigma.ini.usc.edu/protocols/genetics-
protocols/). Further details on the imputation of
unobserved SNP’s to determine APOE status are
described in detail elsewhere [27].
Image acquisition
High resolution 3D T1-weighted MRI were
acquired for each subject and a comprehensive qual-
ity control procedure was applied to all MR images
according to the AddNeuroMed study quality control
framework [24, 28].
ADNI: The protocol included a high resolution
T1 weighted sagittal 3D MP-RAGE volume (voxel
size 1.1 × 1.1 × 1.2 mm³), and axial proton density
with T2 weighted fast spin echo images. MRI scan-
ner protocols from models of General Electric (GE)
Healthcare, Philips Medical Systems, and Siemens
Medical Solutions were supported.
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ANM: Data acquisition took place using six differ-
ent 1.5T MR systems (4 General Electric, 1 Siemens,
and 1 Picker). At each site a quadrature birdcage coil
was used for RF transmission and reception. Data
acquisition was designed to be compatible with the
ADNI. The imaging protocol included a high res-
olution sagittal 3D T1-weighted MPRAGE volume
(voxel size 1.1 × 1.1 × 1.2 mm3) and axial proton
density / T2-weighted fast spin echo images. The
BRC-AD study protocol was designed to be the same
as the ANM protocol.
AIBL: T1-weighted MRI was obtained using
the ADNI 3D Magnetization Prepared Rapid Gra-
dient Echo (MPRAGE) sequence, with 1 × 1 mm
in-plane resolution and 1.2 mm slice thickness,
TR/TE/T1 = 2300/2.98/900, flip angle 9◦ and field
of view 240 × 256 and 160 slices. T2 FSE and
FLAIR sequences were also obtained. The AIBL
protocol has been described in extensive detail
previously [20].
SNAC-K: MRI scanning was undertaken on a 1.5T
scanner (Philips Intera, Netherlands) on which 3D
FFE (fast field echo) T1, Axial SE (spin echo) Pro-
ton Density/T2, DTI (Diffusion Tensor Imaging), and
Axial FLAIR (fluid-attenuated inversion recovery)
were acquired. In this study, the 3D FFE T1 images
(TR = 15 ms, TE = 7 ms, Flip angle = 15◦, number
of slices = 128, thickness = 1.5 mm, in-plane resolu-
tion = 0.94 × 0.94 mm, no gap, Field of view = 240,
matrix = 256∗256) were used.
IMAGEN: MRI images were acquired using 3T
MRI systems from major manufacturers (Siemens,
Philips, Bruker, and General Electric). The protocol
included a high-resolution 3D T1-weighted ultra-
fast gradient echo volume (voxel size 1.1 × 1.1 × 1.1
mm3) and axial proton density T2-weighted fast spin
echo images based on the ADNI study protocol.
Aβ PET methods
Data on A imaging with positron emission
tomography (PET) was accessed for a total of 95
ADNI and 57 AIBL 4 carriers. A imaging for these
subjects was conducted using either 11C-Pittsburgh
Compound B (PiB), or 18F-florbetapir. PET scans
that were acquired as close as possible to the struc-
tural MRI scans in the ADNI and AIBL study were
chosen. The PET imaging methodology of the ADNI
and AIBL studies has been extensively described
elsewhere [29, 30]. For PiB PET, the measure of amy-
loid burden was calculated by averaging the ratio of
cortical to cerebellar signal (SUVR) measurements
from frontal, parietal, anterior cingulate, and pari-
etal regions of interest [29]. For 18F-florbetapir, the
SUVR was calculated for 6 pre-defined regions of
interest (frontal, temporal, parietal, anterior cingu-
late, posterior cingulate, and precuneus). The whole
cerebellum was used as a reference region for both
PiB and 18F-florbetapir PET.
Of the 95 subjects that underwent PET neuroimag-
ing in the ADNI study, 66 were scanned using
18F-florbetapir and 29 using PiB. For the AIBL study,
all subjects underwent PET neuroimaging using PiB.
The global measure of amyloid burden was used to
define participants as A positive (A+) and A
negative (A–). PiB participants were classified as
A+ when the measure of amyloid burden was ≥
1.5 [30] and 18F-florbetapir participants were classi-
fied as A+ if the measure of amyloid burden was ≥
1.11 [31].
Image analysis
Volumetric segmentation of the hippocampus
was performed using FreeSurfer (5.1.0). FreeSurfer
utilizes an affine rigid linear transformation and
combines spatial information about voxel inten-
sity relative to a probability distribution for tissue
classes [32]. The Freesurfer segmentation pro-
cess includes motion correction of volumetric
T1-weighted images, removal of non-brain tissue
using a hybrid watershed/surface deformation pro-
cedure [33], automated Talairach transformation,
segmentation of the subcortical white matter and
deep grey matter volumetric structures (including
hippocampus, amygdala, caudate, putamen, ventri-
cles) [34], intensity normalization [33], tessellation
of the grey matter white matter boundary, auto-
mated topology correction [35, 36], and surface
deformation following intensity gradients to opti-
mally place the grey/white and grey/cerebrospinal
fluid borders at the location where the greatest
shift in intensity defines the transition to the other
tissue class [37–39]. Further details of the seg-
mentation approach have been described previously
[34]. Quality control of hippocampal images were
performed by visualizing the subcortical segmenta-
tion borders of the hippocampus for every subject.
Images reflecting a poor segmentation of the hip-
pocampal structures were excluded from the study.
Hippocampal volumes were normalized by subject
intracranial volume (volumenormalized = volumeraw∗
1,000/intracranial volume) to correct for individual
differences in head size.
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Statistical analysis
To compare demographic statistics, Fisher’s exact
tests and ANOVA with Tukey-Kramer HSD post-hoc
tests were used. A linear mixed model regression was
used to compare hippocampal volumes by APOE
genotype (2/3/4). In accordance with previous
work, 44 2/4 individuals were excluded from the
analysis due to the opposing protective effect of the
2 allele and detrimental effect of 4 allele [40]. The
model treated subject age, gender, and baseline diag-
nosis as fixed terms in the final model. Interaction
terms for APOE genotype and diagnosis were also
included and image acquisition site was included as
a random effect term.
Hippocampal comparisons were also performed
in a sample of subjects from the ADNI and AIBL
cohorts who were divided into A+ and A– partici-
pants. Pairwise multiple comparisons were corrected
using a stringent Bonferroni correction method. The
R statistical software environment, version 3.1.1, was
used to perform all statistical analyses in RStudio.
The nlme v3.1–117 [41] package was used to cre-
ate linear-mixed effects models and multcomp v1.3–6
[42] package for post-hoc comparisons.
RESULTS
Demographic characteristics
In the AD group, a difference in age between
APOE groups was significant (p = 0.016) with 2 car-
riers being significantly older than 3 carriers and
4 carriers. For MCI subjects, 2 and 3 carriers
had significantly higher MMSE scores than 4 carri-
ers (p = 0.016). No other demographic characteristics
differed between the groups (Table 2).
Comparing the effect of APOE genotype on
hippocampal volume in the AD, and normal
aging dataset (n = 1,781) and the IMAGEN study
of healthy 14-year-old adolescents (n = 1,387)
In AD patients, 4 carriers had significantly
smaller hippocampal volumes than non-carriers. A
significant linear stepwise reduction in hippocampal
volume was observed with 2 carriers possessing the
largest volumes, 3 carriers possessing intermediate
volumes and 4 carriers possessing the smallest vol-
umes. This pattern was also observed in the MCI
group (Table 3). The effect of the 4 allele on
hippocampal volume was found to be moderately
dose-dependent in AD patients [left region: Cohen’s
d = 0.10, p≤ 0.0001; right region: Cohen’s d = 0.22,
p≤ 0.0001] and MCI subjects [left region: Cohen’s
d = 0.15, p≤ 0.0001; right region: Cohen’s d = 0.19,
p≤ 1].
The effect of APOE genotype on hippocam-
pal volumes in CN individuals was not significant
(left region: p = 0.052; right region: p = 0.053) and
the magnitude of this non-significant difference in
both regions was small (Cohen’s d = 0.16; effect
size r = 0.08). This non-significant pattern was also
observed in elderly individuals from the SNAC-K
study, as well as in healthy adolescents from the IMA-
GEN study (Table 3). Figure 1 displays hippocampal
volumes by APOE genotype in the AD and normal
aging dataset and IMAGEN study of adolescents.
Hippocampal volumes of AD 4 carriers were
found to be significantly smaller than MCI, CN,
and non-demented 4 carriers. This pattern was also
observed in MCI 4 carriers who had significantly
smaller volumes than CN, and non-demented 4 car-
riers (Table 4). In carriers of the 2 allele, the MCI
and CN groups possessed significantly larger hip-
pocampal volumes than 2 carriers of the AD group
(Table 5).
Comparison of hippocampal volumes by ApoE
4 and Aβ deposition
In this analysis, 4 carriers from the ADNI and
AIBL cohort studies were selected and divided into
A+ and A– participants to assess if the effect of
APOE 4 on the hippocampus is modified by lev-
els of A deposition. Descriptive information for
this sample is shown in Table 6. Among 4 + CN
individuals, hippocampal volumes between A+
and A– participants did not significantly differ
(left region: p = 0.692; right region: p = 0.946). MCI
A+ participants were found to have significantly
smaller hippocampal volumes than MCI A– partic-
ipants for the right hippocampus (left hippocampus:
p = 0.295; right hippocampus: p = 0.054). Hippocam-
pal volumes of MCI A+4 + participants did not
differ when compared to AD A+4 + participants.
AD A+4 + participants possessed significantly
smaller hippocampal volumes than (i) the CN A–
4 + group (left region: Cohen’s d = –1.05; p≤ 0.001;
right region: Cohen’s d = –1.03; p≤ 0.001) and
the (ii) CN A+4 + group (left region: Cohen’s
d = –1.09; p≤ 0.001; right region: Cohen’s d = –1.02;
p≤ 0.001). The complete results for these compar-
isons are shown in Table 7. There was no interaction
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Table 2
Demographic characteristics of 1) the AD and normal aging dataset by subject group and 2) the IMAGEN study of healthy adolescents
2 carriers 3 carriers 4 carriers
(n = 344) (n = 1754) (n = 1070)
2/3 (n = 326) 3 4/3 (n = 893) p-value
2/2 (n = 18) Homozygotes 4/4 (n = 177)
AD and Normal Aging Dataset (n = 1,781)
i) AD (n = 375)
Number of subjects (n (%))† 17 (4.5) 125 (33.3) 223 (59.5) ––
Age (years) 78.1± 6.6 76.9± 7.4 74.9± 6.7 0.016
Male (n (%)) 4 (23.5) 56 (44.8) 112 (50.2) 0.085
Education† 12.0 ± 3.6 11.8 ± 5.1 12.2 ± 4.5 0.847
MMSE 21.3 ± 5.8 22.1 ± 4.1 22.1 ± 3.7 0.734
ICV (mL) 1437 ± 165 1520 ± 166 1532 ± 188 0.110
ii) MCI (n = 522)
Number of subjects (n (%))† 29 (5.6) 233 (44.6) 260 (49.8) ––
Age (years) 75.6 ± 7.1 75.3 ± 7.5 74.2 ± 6.9 0.186
Male (n (%)) 15 (2.9) 144 (27.6) 152 (29.1) 0.508
MMSE 27.6± 1.4 27.1± 1.8 26.8± 1.8 0.016
ICV (mL) 1491 ± 173 1558 ± 173 1559 ± 169 0.123
iii) CN individuals (n = 512)
Number of subjects (n (%)) 66 (12.9) 275 (53.7) 171 (33.4) ––
Age (years) 75.8 ± 6.5 75.9 ± 6.3 75.6 ± 6.2 0.936
Male (n (%)) 28 (5.5) 139 (27.1) 84 (16.4) 0.495
MMSE 28.9 ± 1.1 29.0 ± 1.1 29.1 ± 1.1 0.537
ICV (mL) 1506 ± 174 1521 ± 162 1518 ± 160 0.797
iv) SNAC-K (n = 382)
Number of subjects (n (%))† 45 (11.8) 239 (62.6) 98 (25.7) ––
Age (years) 67.9 ± 7.8 70.1 ± 8.6 69.5 ± 8.6 0.269
Male (n (%)) 15 (3.9) 102 (26.7) 37 (9.7) 0.420
MMSE 29.2 ± 0.9 29.2 ± 1.0 29.1 ± 1.1 0.365
ICV (mL) 1478 ± 265 1509 ± 248 1522 ± 275 0.649
1) IMAGEN (n= 1,387)
Number of subjects (n (%))† 187 (13.5) 882 (63.6) 318 (22.9) ––
Age (years) 14.4 ± 0.4 14.5 ± 0.4 14.5 ± 0.4 0.523
Male (n (%)) 97 (7.0) 437 (31.5) 152 (11) 0.674
Body Mass Index (BMI) 20.6 ± 3.2 20.7 ± 3.6 20.8 ± 3.3 0.843
CANTAB SWM 31.3 ± 5.3 31.2 ± 5.5 31.0 ± 5.5 0.866
Verbal IQ 109.6 ± 15.7 111.6 ± 15.5 111.0 ± 14.9 0.258
Nonverbal IQ 106.5 ± 14.9 107.8 ± 14.4 107.7 ± 14.1 0.523
ICV (mL) 1472 ± 155 1487 ± 156 1490 ± 162 0.397
MMSE, Mini-Mental State Examination; ICV, intracranial volume; CANTAB SWM, Cambridge Neuropsychological Test Automated Battery
[CANTAB] Spatial Working Memory; IQ, intelligence quotient. Data are Mean ± SD. Percentages are displayed in parentheses.
observed between gender and 4 status in hip-
pocampal volumes between groups. Hippocampal
differences between the different A+ and A– par-
ticipants are shown in Fig. 2.
DISCUSSION
Prior neuroimaging studies of APOE 4 have
helped define our current observation of structural
changes in the brain, but the mechanisms associated
with the detrimental effect of APOE 4, particu-
larly across the different stages of AD, still remains
poorly understood. With recent studies proposing a
neurodevelopmental foothold of APOE 4 on the
brain [43, 44], understanding whether atrophy in
AD-susceptible areas, such as the hippocampus, are
attributed to pre-clinical manifestations of the dis-
ease, or whether these constitute a part of non-specific
normal aging is of great importance for earlier
diagnosis.
Here we present the largest cross-sectional multi-
cohort study of APOE and hippocampal volume to
date (n = 3,168) and discuss a number of key find-
ings. Firstly, a linear neuroanatomic effect of the
APOE genotype was observed for hippocampal vol-
umes of AD and MCI subjects, whereby 4 carriers
presented with the lowest volumes, 3 homozygotes
possessed intermediate volumes, and 2 carriers pos-
sessed the largest volumes. As expected, 4 carriers
in the AD and the MCI group had significantly
lower hippocampal volumes when compared to CN
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Table 3
Hippocampal volume results by ApoE genotype in each subject group





Left Hippocampus 2.00 1.91 1.80 0.0001 –2.2 4<3 = 0.0006;
(0.11; 1.77–2.22) (0.04; 1.83–1.97) (0.02; 1.75–1.84) 4<2 = 0.07;
3<2 = 0.86
Right Hippocampus 2.04 1.98 1.81 <0.0001 –2.3 4<3 = <0.0001;




Left Hippocampus 2.22 2.09 1.97 <0.0001 –3.4 4<3 = 0.0004;
(0.06; 2.09–2.35) (0.03; 2.03–2.14) (0.02; 1.93–2.02) 4<2 = 0.0015;
3<2 = 0.19
Right Hippocampus 2.27 2.13 2.01 <0.0001 –3.3 4<3 = < 0.0001;
(0.06; 2.14–2.39) (0.03; 2.07–2.18) (0.02; 1.97–2.05) 4<2 = 0.0019;
3<2 = 0.22
Healthy Controls (n = 512)
Left Hippocampus 2.40 2.36 2.30 0.052 –1.9 4<3 = 0.076;
(0.04; 2.32–2.47) (0.02; 2.32–2.40) (0.03; 2.25–2.36) 4<2 = 0.367;
3<2 = 0.865
Right Hippocampus 2.43 2.39 2.33 0.053 –2.0 4<3 = 0.085;




SNAC-K study (n= 382)
Left Hippocampus 2.72 2.56 2.56 0.395 –1.9 4<3 = 0.660;
(0.08; 2.56–2.87) (0.03; 2.49–2.62) (0.06; 2.45–2.67) 4<2 = 0.367;
3<2 = 0.669
Right Hippocampus 2.66 2.53 2.53 0.509 –2.0 4<3 = 0.625;
(0.08; 2.50–2.82) (0.03; 2.46–2.59) (0.06; 2.42–2.64) 4<2 = 0.530;
3<2 = 0.868
Healthy 14-year-old adolescents:
IMAGEN study (n= 1,387)
Left Hippocampus 2.88 2.86 2.88 0.972 –0.3 4<3 = 0.714;
(0.02; 2.84–2.93) (0.01; 2.84–2.88) (0.02; 2.84–2.92) 4<2 = 0.960;
3<2 = 0.611
Right Hippocampus 2.95 2.91 2.94 0.751 –0.8 4<3 = 0.399;
(0.02; 2.91–3.00) (0.01; 2.89–2.93) (0.02; 2.91–2.97) 4<2 = 0.731;
3<2 = 0.136
Data are mean (SE; min-max). Mean values of normalized hippocampal volumes are reported.
individuals and a population-based sample of elderly
non-demented individuals from the SNAC-K study.
These findings are in agreement with previous stud-
ies demonstrating a distinct neuroanatomic effect of
APOE genotype on brain structure, as well as studies
reporting smaller hippocampal volumes in MCI sub-
jects with prodromal stages of AD. Furthermore, our
finding of larger hippocampal volumes in 2 carri-
ers in older healthy groups supports the 2 allele’s
suggested effect of protection against neurodegenera-
tion. Previous cellular models have advocated its role
in a disease staving protective effect, in particular its
ability to modify the neuropathological effects of A
accumulation [45].
The absence of APOE-dependent hippocampal
volume loss in CN individuals and in a population-
based sample of elderly individuals suggested
that APOE 4 may not be independently associ-
ated with hippocampal atrophy in normal aging.
Although the findings from previous APOE studies
in non-demented individuals are mixed, our findings
replicate a number of earlier neuroimaging stud-
ies showing no effect of APOE 4 on regions such
as the hippocampus in normal aging [46–48]. One
explanation for the discrepant APOE findings in CN
individuals may be related to differences in defining
those that fulfil the criteria for pre-clinical AD from
subjects showing typical normal aging [11]. Recent
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Fig. 1. Hippocampal volumes and ApoE genotype in the AD and normal aging dataset and IMAGEN study. Shown are hippocampal
volumes from (a) the left and (b) the right region in the AD and normal aging dataset by baseline diagnosis ApoE genotype (2 carriers,
3 homozygotes, and 4 carriers). Hippocampal volumes from (c) the left and (d) right region of healthy 14-year-old adolescents in the
IMAGEN study. SNAC-K indicates Swedish National study on Aging and Care in Kungsholmen.
Table 4
Hippocampal volume comparisons of ApoE 4 carriers (4+) from different subject groups
AD 4 + group MCI 4 + group healthy controls SNAC-K elderly p-value Pairwise Difference
(n = 223) (n = 260) 4 + group 4 + group (t-value; p-value)
(n = 171) (n = 98)
3/4 (n = 159) 3/4 (n = 203) 3/4 (n = 151) 3/4 (n = 84)
4/4 (n = 64) 4/4 (n = 57) 4/4 (n = 20) 4/ 4 (n = 14)
Left Hippocampus 1.79 1.97 2.30 2.56 <0.0001 AD versus MCI = –5.7; <0.001
(0.02; 1.75–1.84) (0.02; 1.93–2.02) (0.03; 2.25–2.36) (0.06; 2.45–2.67) AD versus CTL = –14.0; <0.001
AD versus SNAC-K = –8.7; <0.001
MCI versus CTL = –9.0; <0.001
MCI versus SNAC-K = –6.3; <0.001
SNACK versus CTL = 1.9; 0.208
Right Hippocampus 1.81 2.01 2.33 2.53 <0.0001 AD versus MCI = –6.0; <0.001
(0.02; 1.77–1.86) (0.02; 1.97–2.05) (0.03; 2.27–2.39) (0.06; 2.42–2.64) AD versus CTL = –13.4; <0.001
AD versus SNAC-K = –7.9; <0.001
MCI versus CTL = –8.1; <0.001
MCI versus SNAC-K = –5.3; <0.001
SNAC-K versus CTL = 1.2; 0.579
Data are presented as the mean of normalized hippocampal volumes (Volume/ICV×1000). SE with min-max is shown in parentheses.
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Table 5
Hippocampal volume comparisons of ApoE 2 carriers (2+) from different subject groups
AD 2 + group MCI 2 + group healthy controls SNAC-K elderly p-value Pairwise Difference
(n = 17) (n = 29) 2 + group 2 + group (t-value; p-value)
(n = 66) (n = 45)
3/2 (n = 17) 3/2 (n = 29) 3/2 (n = 64) 3/2 (n = 42)
2/2 (n = 0) 2/2 (n = 0) 2/2 (n = 2) 2/2 (n = 3)
Left Hippocampus 2.00 2.22 2.40 2.72 0.0003 AD versus MCI = –2.1; 0.141
(0.11; 1.77–2.22) (0.06; 2.09–2.35) (0.04; 2.32–2.47) (0.08; 2.56–2.87) AD versus CTL = –4.0;<0.001
AD versus SNAC-K = –3.6; 0.002
MCI versus CTL = –1.9; 0.211
MCI versus SNAC-K = –2.1; 0.137
SNAC-K versus CTL = 1.0; 0.753
Right Hippocampus 2.04 2.27 2.43 2.66 0.0035 AD versus MCI = –2.1; 0.144
(0.12; 1.80–2.29) (0.06; 2.14–2.39) (0.04; 2.35–2.51) (0.08; 2.50–2.82) AD versus CTL = –3.8;<0.001
AD versus SNAC-K = –2.1; 0.129
MCI versus CTL = –1.5; 0.410
MCI versus SNAC-K = –0.9; 0.796
SNAC-K versus CTL = 0.2; 0.998
Table 6
Demographic characteristics of 4 carriers from the ADNI and AIBL study divided into A+ and A– participants
AD A+ MCI A+ MCI A– CN A+ CN A– p-value
ADNI study (n = 95)
Number of subjects (n (%)) 8 (8.4) 58 (61.0) 7 (7.4) 14 (14.7) 8 (8.4) ––
Age (years) 70.2± 7.3 72.5± 7.3 77.3± 4.9 77.1± 3.4 75.1± 4.0 0.041
Male (%) 4 (7.1) 37 (66.1) 5 (8.9) 4 (7.1) 6 (10.7) 0.113
MMSE 23± 1.7 27.2± 1.7 27.1± 1.9 29.4± 0.8 29.4± 0.9 <0.001
ICV (mL) 1556 ± 210 1583 ± 198 1494 ± 176 1429 ± 98 1591 ± 209 0.08
AIBL study (n = 57)
Number of subjects (n (%)) 7 (12.2) 1 (1.8) 3 (5.3) 20 (35.0) 26 (45.6) ––
Age (years) 77.7± 7.8 58± –– 79.7± 12.0 78.1± 6.5 71.5± 5.8 0.001
Male (%) 1 (3.7) 1 (3.7) 1 (3.7) 10 (37.0) 14 (51.9) 0.296
MMSE 19.4± 3.8 27.0± –– 27.7± 2.5 27.4± 3.1 27.2± 4.3 <0.001
ICV (mL) 1466 ± 87 1515 ± –– 1592 ± 301 1535 ± 159 1545 ± 165 0.781
MMSE, Mini-Mental State Examination; ICV, intracranial volume. Bolded values are significant at p < 0.05 or the p < 0.001 level. In the
ADNI study, of the 95 subjects who underwent PET neuroimaging, 66 were scanned using 18F-florbetapir and 29 using 11C-Pittsburgh
Compound B (PiB). In the AIBL study, all subjects underwent PET neuroimaging using PiB.
Table 7
Hippocampal volume results in CN individuals, MCI subjects, and AD patient 4 carriers by levels of A deposition
CN A– CN A+ MCI A– MCI A+ AD A+ p-value Pairwise Difference
(n = 34) (n = 34) (n = 10) (n = 27) (n = 15) (Cohen’s d; p-value)
(versus CN A– 4+)
Left Hippocampus 2.42 (0.052) 2.39 (0.053) 2.18 (0.095) 1.97 (0.04) 1.88 (0.078) <0.0001 CN A+ = –0.08; 0.692
MCI A– = –0.42;<0.0001
MCI A+ = –1.26;<0.0001
AD A+ = –1.09;<0.0001
Right Hippocampus 2.45 (0.056) 2.44 (0.058) 2.27 (0.01) 1.94 (0.043) 1.90 (0.084) <0.0001 CN A+ = –0.01; 0.946
MCI A– = –0.29; 0.147
MCI A+ = –1.26;<0.0001
AD A+ = –1.02;<0.0001
Data are presented as the estimated marginal mean of normalized hippocampal volumes and SE in parentheses. MCI follow diagnosis was
available for ADNI (0–36 months) and AIBL (0–54 months).
studies have since shown that APOE 4 is linked to
A deposition and may exert a synergistic effect to
promote cognitive decline [49, 50].
To test whether an A-dependent effect of APOE
4 would be associated with greater hippocampal
volume loss, we examined the combined effect
of APOE 4 and A on the hippocampus. We
found no significant differences in hippocampal
volume between CN A+4 + individuals and CN
A– 4 + individuals, suggesting that in healthy

































Fig. 2. Hippocampal volumes of 4 carriers by diagnosis and A. Data was used from the ADNI and AIBL cohorts for subjects that had
available PET A. MCI subjects were further divided by follow-up diagnosis in ADNI (0–36 months) and AIBL (0–54 months). Shown are
baseline hippocampal volumes from (a) the left and (b) the right region. Note: There were no MCI-nc A– 4 carriers that converted to AD
during the current follow-up period of the ADNI and AIBL studies. A, amyloid-; CN, cognitively normal; CN A–, A– negative CN
group; CN A+, A positive CN group; MCI, mild cognitive impairment; MCI A–, A negative MCI group; MCI-c, MCI non-converter;
MCI-nc A+, A positive MCI-nc group; MCI-c, MCI-converter; MCI-c A+, A positive MCI-c group; AD, Alzheimer’s disease; AD
A+, A positive AD group.
individuals there is no effect of APOE 4 and
A on the hippocampus. This is consistent with
previous studies that have shown that the relation-
ship between APOE 4, A, and brain atrophy
is mediated by CSF p-tau181 levels [51, 52] and,
in the absence of abnormal p-tau181 levels, there
is no synergistic relationship between APOE 4
and A deposition. Hippocampal volumes of MCI
A+4+ individuals did not differ when compared to
AD A+4+ participants, suggesting that a similar
degree of hippocampal loss that is expected in AD
has already manifested in MCI subjects. Our find-
ings are supported by empirical evidence which has
shown that APOE induces intracellular degradation
of A peptides facilitating synaptotoxicity, neuroin-
flammation, and tau hyperphosphorylation [5, 53]. It
is therefore possible that A and the 4 in conjunction
impart great levels of neuronal toxicity and injury in
the presence of hippocampal neurodegeneration.
Recent studies have suggested an A independent
effect of the APOE4 on neuronal integrity as another
explanation for the gene’s effect on brain structure
[47, 54]. A study by Dean and colleagues [44] argued
that an early neurodevelopmental foothold of APOE
on the brain may render individuals more suscepti-
ble to the toxic and downstream neurodegenerative
effects of A later in life. However, findings from
our large sample of 14-year-old adolescents showed
that there were no hippocampal volume differences
present between the APOE groups, suggesting that
4 carriers are unlikely to be at risk in adolescence,
but may perhaps develop a greater risk later in life.
Similar studies, such as that of O’Dwyer and col-
leagues [15] reported lower hippocampal volumes
in 4 carriers aged in their mid-twenties. Although
differences may be attributed to the methodological
approach adopted for the automated segmentation of
the hippocampus, we cannot exclude the possibility
of a low APOE penetrance in our young sample. Nev-
ertheless, previous studies in younger 4 carriers have
shown that APOE plays a fundamental role in modu-
lating brain function in the absence of any differences
in brain volume [47].
An important caveat when interpreting the results
of this study is that the multi-cohort data was cross-
sectional and a more complete understanding of how
hippocampal trajectories vary with age would require
longitudinal data. In particular, more neuroimaging
studies need to be conducted into typical cognitive
aging across the lifespan [18] in order to differ-
entiate between brain changes that are associated
with typical normal aging from those that arise from
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APOE 4 dependent mechanisms and-amyloidosis.
Additionally, when combining data across cohort
studies, it is important to consider study design dif-
ferences that may complicate the interpretation of
our results. For instance, the use of different AD
diagnostic criteria across the different cohort stud-
ies may contribute to a level of diagnostic variability
between groups. Participants from the ADNI and
AIBL study were also highly educated, had few
comorbidities, and were of Caucasian background.
As such, future prospective studies with more rep-
resentative samples should be conducted to address
how these comorbidities, namely the presence of vas-
cular disease, could potentially influence the size
of the hippocampus. We demonstrated that sys-
tematic bias was not present in our dataset when
comparing hippocampal volumes between APOE
groups within each cohort study separately (Supple-
mentary Material). Additional factors such as the
use of two different PET radioligands meant that
SUVR values of tracer uptake could not be compared
as a single continuous measure. However, ongoing
working groups such as the Centiloid project will
further enable a more standardized approach for the
direct comparability of results across different labs
when different tracers and methods of analysis are
employed [55].
Despite these limitations, this is first multi-cohort
neuroimaging study of APOE genotype that attempts
to characterize the differential risk of APOE on hip-
pocampal volumes of subjects with varying stages of
AD. Using metadata and clinical phenotyping pooled
across several cohort studies, we were systematically
able to demonstrate differential effects of the different
APOE gene polymorphisms on hippocampal volume.
An independent sample of healthy 14-year-old ado-
lescents also provides an understanding into the role
of APOE in adolescent brain neurodevelopment.
In conclusion, our findings in the largest APOE
neuroimaging dataset show that hippocampal volume
loss is present in patients with AD and in subjects
with an increased risk of developing AD, particularly
subjects with memory impairment. However, healthy
older individuals did not show APOE 4 dependent
changes in the hippocampus, suggesting that the rela-
tionship between APOE 4 and A may be mediated
by the presence of neurodegeneration. The same pat-
tern was also observed in healthy young adolescents
who possessed no hippocampal differences between
different APOE groups. Our study thus shows hip-
pocampal volume loss is moderated by APOE 4 and
A in AD and the MCI stages of the AD pathological
process. The influence of these three markers could
be considered as prognostic tools in clinical trials and
therapeutic interventions of AD.
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